Marksans Pharma's Q2 FY 2025-26 Quarterly Results

Result Summary

• Marksans Pharma Ltd reported a 18.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 13.6%.
• Its expenses for the quarter were up by 10.9% QoQ and 15.2% YoY.
• The net profit increased 70.3% QoQ and increased 1.4% YoY.
• The earnings per share (EPS) of Marksans Pharma Ltd stood at 2.17 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Marksans Pharma Ltd is a pharmaceutical company involved in the development, manufacturing, and marketing of generic pharmaceutical products. The company operates within the healthcare industry, providing a range of products that cater to various therapeutic segments. Marksans Pharma is known for its production of over-the-counter (OTC) drugs, prescription drugs, and active pharmaceutical ingredients (APIs). The company strives to expand its global footprint by enhancing its product portfolio and scaling its manufacturing capabilities. As of the data provided, specific recent developments about the company are not available.

Revenue

In the quarter ending Q2FY26, Marksans Pharma Ltd reported a total income of ₹741.98 crores. This represents an 18.6% increase from the previous quarter (Q1FY26), where the total income was ₹625.63 crores. Comparing year-over-year, there was a 13.6% rise in total income from Q2FY25, when total income was ₹652.98 crores. These figures highlight a consistent growth in revenue both on a quarter-over-quarter and year-over-year basis, reflecting the company's ability to generate increased sales over the periods analyzed.

Profitability

For the quarter ending Q2FY26, the company recorded a profit before tax of ₹133.33 crores, marking a substantial increase of 74.1% compared to Q1FY26, where the profit before tax was ₹76.60 crores. On a year-over-year basis, there was a 7.0% increase from Q2FY25's profit before tax of ₹124.60 crores. Profit after tax for Q2FY26 was ₹99.14 crores, up by 70.3% from Q1FY26, which stood at ₹58.20 crores, and a slight year-over-year increase of 1.4% from Q2FY25's ₹97.76 crores. These figures suggest that the company has managed to improve its profitability, with significant quarterly improvements.

Operating Metrics

In Q2FY26, Marksans Pharma Ltd's total expenses stood at ₹608.66 crores, increasing by 10.9% from the previous quarter (Q1FY26) expenses of ₹549.03 crores. Year-over-year, there was a 15.2% increase from Q2FY25's expenses of ₹528.38 crores. The tax expense for Q2FY26 was ₹34.20 crores, up 85.9% from Q1FY26's tax expense of ₹18.40 crores and an increase of 27.4% from Q2FY25's ₹26.84 crores. Earnings per share (EPS) for Q2FY26 was reported at ₹2.17, growing by 68.2% from Q1FY26's EPS of ₹1.29 and a 1.9% increase from Q2FY25's EPS of ₹2.13. These metrics provide a comprehensive overview of the company's operational expenditure and shareholder profitability over the respective periods.